Baseline characteristics according to the medullary pattern of the AS
| Characteristic . | Entire cohort, n = 196 . | Fatty, n = 75 . | Focal/scattered, n = 81 . | Diffuse, n = 40 . | P . |
|---|---|---|---|---|---|
| Age, median (range), y | 72.2 (30-90) | 73.3 (52-88) | 72.2 (43-90) | 70.4 (30-87) | .33 |
| Male sex, n (%) | 102 (52.0) | 46 (61.3) | 36 (44.4) | 20 (50.0) | .1 |
| M-protein type, n (%) | |||||
| IgG | 102 (52.0) | 43 (57.3) | 46 (56.8) | 13 (32.5) | .021 |
| IgA | 53 (27.0) | 21 (28.0) | 17 (21.0) | 15 (37.5) | .15 |
| Other | 41 (21.0) | 11 (14.7) | 18 (22.2) | 12 (30.0) | .15 |
| Kappa light chain type, n (%) | 108 (55.1) | 35 (46.7) | 48 (59.3) | 25 (62.5) | .17 |
| D-S stage 3, n (%) | 132 (67.4) | 31 (41.3) | 67 (82.7) | 34 (85.0) | <.001 |
| R-ISS stage 3, n (%)* | 55 (28.5) | 9 (12.2) | 27 (33.8) | 19 (48.7) | <.001 |
| del(17p), n (%)† | 11 (5.8) | 1 (1.4) | 7 (8.8) | 3 (7.9) | .121 |
| t(4;14), n (%)‡ | 25 (12.8) | 6 (8.0) | 13 (16.0) | 6 (15.4) | .28 |
| t(14;16), n (%)§ | 3 (1.6) | 1 (1.4) | 0 (0.0) | 2 (5.1) | .107 |
| Creatinine level >2.0 mg/dL, n (%) | 38 (19.4) | 9 (12.0) | 16 (19.8) | 12 (32.5) | .03 |
| HDT + ASCT, n (%) | 49 (25.0) | 19 (25.3) | 19 (23.5) | 11 (27.5) | .89 |
| CD56 positivity, n (%)|| | 147 (75.0) | 58 (78.4) | 58 (71.6) | 31 (77.5) | .58 |
| Circulating PCs ≥0.1% MNCs, n (%)¶ | 58 (49.6) | 14 (37.8) | 30 (55.6) | 14 (53.8) | .22 |
| BM PC, median (IQR), %# | 70 (43.8-90.0) | 50 (30.0-70.0) | 80 (50.0-90.0) | 90 (60.0-100.0) | <.001 |
| Best response, n (%)** | |||||
| CR | 95 (50.1) | 46 (62.5) | 35 (44.9) | 15 (40.5) | .037 |
| Maintenance therapy after CR, n (%) | 65 (68.4) | 32 (71.1) | 24 (68.6) | 9 (60.0) | .73 |
| Characteristic . | Entire cohort, n = 196 . | Fatty, n = 75 . | Focal/scattered, n = 81 . | Diffuse, n = 40 . | P . |
|---|---|---|---|---|---|
| Age, median (range), y | 72.2 (30-90) | 73.3 (52-88) | 72.2 (43-90) | 70.4 (30-87) | .33 |
| Male sex, n (%) | 102 (52.0) | 46 (61.3) | 36 (44.4) | 20 (50.0) | .1 |
| M-protein type, n (%) | |||||
| IgG | 102 (52.0) | 43 (57.3) | 46 (56.8) | 13 (32.5) | .021 |
| IgA | 53 (27.0) | 21 (28.0) | 17 (21.0) | 15 (37.5) | .15 |
| Other | 41 (21.0) | 11 (14.7) | 18 (22.2) | 12 (30.0) | .15 |
| Kappa light chain type, n (%) | 108 (55.1) | 35 (46.7) | 48 (59.3) | 25 (62.5) | .17 |
| D-S stage 3, n (%) | 132 (67.4) | 31 (41.3) | 67 (82.7) | 34 (85.0) | <.001 |
| R-ISS stage 3, n (%)* | 55 (28.5) | 9 (12.2) | 27 (33.8) | 19 (48.7) | <.001 |
| del(17p), n (%)† | 11 (5.8) | 1 (1.4) | 7 (8.8) | 3 (7.9) | .121 |
| t(4;14), n (%)‡ | 25 (12.8) | 6 (8.0) | 13 (16.0) | 6 (15.4) | .28 |
| t(14;16), n (%)§ | 3 (1.6) | 1 (1.4) | 0 (0.0) | 2 (5.1) | .107 |
| Creatinine level >2.0 mg/dL, n (%) | 38 (19.4) | 9 (12.0) | 16 (19.8) | 12 (32.5) | .03 |
| HDT + ASCT, n (%) | 49 (25.0) | 19 (25.3) | 19 (23.5) | 11 (27.5) | .89 |
| CD56 positivity, n (%)|| | 147 (75.0) | 58 (78.4) | 58 (71.6) | 31 (77.5) | .58 |
| Circulating PCs ≥0.1% MNCs, n (%)¶ | 58 (49.6) | 14 (37.8) | 30 (55.6) | 14 (53.8) | .22 |
| BM PC, median (IQR), %# | 70 (43.8-90.0) | 50 (30.0-70.0) | 80 (50.0-90.0) | 90 (60.0-100.0) | <.001 |
| Best response, n (%)** | |||||
| CR | 95 (50.1) | 46 (62.5) | 35 (44.9) | 15 (40.5) | .037 |
| Maintenance therapy after CR, n (%) | 65 (68.4) | 32 (71.1) | 24 (68.6) | 9 (60.0) | .73 |
ASCT, autologous stem cell transplantation; BM, bone marrow; D-S, Durie-Salmon; HDT, high-dose therapy; IgG, immunoglobulin G; IQR, interquartile range; MNC, mononuclear cell.
n = 189 (fatty, n = 74; focal/scattered, n = 76; diffuse, n = 39).
n = 191 (fatty, n = 73; focal/scattered, n = 80; diffuse, n = 38).
n = 195 (fatty, n = 75; focal/scattered, n = 81; diffuse, n = 39).
n = 191 (fatty, n = 73; focal/scattered, n = 79; diffuse, n = 39).
n = 185 (fatty, n = 70; focal/scattered, n = 78; diffuse, n = 37).
n = 117 (fatty, n = 37; focal/scattered, n = 54; diffuse, n = 26).
The percentage of BM PCs was quantified by CD138 immunohistochemistry.
n = 187 (fatty, n = 72; focal/scattered, n = 78; diffuse, n = 37).